Literature DB >> 12826739

Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease.

Yong-Xin Sun1, L Minthon, A Wallmark, S Warkentin, K Blennow, S Janciauskiene.   

Abstract

It has been suggested that a number of molecules associated with inflammation are involved in the pathogenesis of Alzheimer's disease (AD). We measured the levels of alpha(1)-antichymotrypsin (ACT), alpha(1)-antitrypsin (AAT), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1) and oxidised low-density lipoprotein (oxLDL) in matched cerebrospinal fluid (CSF) and plasma of 141 patients with probable AD. We found a significant relationship between CSF and plasma levels of ACT (r = 0.4, p < 0.001), IL-6 (r = 0.74, p < 0.001), MCP-1 (r = 0.71, p < 0.001), and a borderline relationship between CSF and plasma oxLDL (r = 0.22, p < 0.05). In addition, linear regression analysis revealed a positive correlation between levels of CSF-ACT and oxLDL (p < 0.001), but an inverse relation between levels of CSF ACT, CSF AAT and MCP-1 (p < 0.001). A significant correlation was also found between levels of CSF ACT, oxLDL and the ratio of CSF to serum albumin, which is used as a measure of the blood-brain barrier function. Our data extend previous reports regarding the inflammatory markers in the plasma and CSF of patients with AD and provide good evidence that levels of ACT, IL-6, MCP-1 and oxLDL in plasma and CSF might be candidates as biomarkers for monitoring the inflammatory process in AD. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12826739     DOI: 10.1159/000071001

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  55 in total

1.  Fibrillar amyloid-beta-activated human astroglia kill primary human neurons via neutral sphingomyelinase: implications for Alzheimer's disease.

Authors:  Arundhati Jana; Kalipada Pahan
Journal:  J Neurosci       Date:  2010-09-22       Impact factor: 6.167

Review 2.  Laboratory biomarkers in Alzheimer's disease.

Authors:  Joshua R Steinerman; Lawrence S Honig
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

3.  Alzheimer's disease and the Blood-Brain Barrier: Past, Present and Future.

Authors:  Gene L Bowman; Joseph F Quinn
Journal:  Aging health       Date:  2008-02-01

Review 4.  Role of cerebrospinal fluid and plasma biomarkers in the diagnosis of neurodegenerative disorders and mild cognitive impairment.

Authors:  Luis F Gonzalez-Cuyar; Joshua A Sonnen; Kathleen S Montine; C Dirk Keene; Thomas J Montine
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

5.  A Precision Medicine Model for Targeted NSAID Therapy in Alzheimer's Disease.

Authors:  Sid E O'Bryant; Fan Zhang; Leigh A Johnson; James Hall; Melissa Edwards; Paula Grammas; Esther Oh; Constantine G Lyketsos; Robert A Rissman
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 6.  Biomarkers of oxidative damage and inflammation in Alzheimer's disease.

Authors:  Douglas Galasko; Thomas J Montine
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

Review 7.  Antioxidants in Down syndrome.

Authors:  Ira T Lott
Journal:  Biochim Biophys Acta       Date:  2011-12-21

8.  Lysophosphatidic acid induces increased BACE1 expression and Aβ formation.

Authors:  Jing Shi; Yunzhou Dong; Mei-Zhen Cui; Xuemin Xu
Journal:  Biochim Biophys Acta       Date:  2012-10-02

9.  The S-adenosyl homocysteine hydrolase inhibitor 3-deaza-adenosine prevents oxidative damage and cognitive impairment following folate and vitamin E deprivation in a murine model of age-related, oxidative stress-induced neurodegeneration.

Authors:  Thomas B Shea; David Ashline; Daniela Ortiz; Shelia Milhalik; Eugene Rogers
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

10.  Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals.

Authors:  Carina Sihlbom; Pia Davidsson; Magnus Sjögren; Lars-Olof Wahlund; Carol L Nilsson
Journal:  Neurochem Res       Date:  2008-02-21       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.